THERE ARE NEWER DRUGS ON THE WAY THAT DON’T TO THIS: Studies exploring muscle loss from GLP-1 drugs
THERE ARE NEWER DRUGS ON THE WAY THAT DON’T TO THIS: Studies exploring muscle loss from GLP-1 drugs. I’d like to see a medication that combines fat loss with myostatin inhibition to promote muscle growth. And apparently there’s one on the way! So Americans will be skinny and hot. And no doubt leftists will complain.
Hundreds of weight loss and diabetes jab users report pancreas problems
UK health officials launch study into side-effects of weight loss drugs after increased reports of acute pancreatitis Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes injections, prompting health officials to launch a study into side-effects. Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like […]
Novo Nordisk A/S (NVO): A Bull Case Theory
We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bull’s thesis on NVO. Novo Nordisk A/S’s share was trading at $70.73 as of June 24th. NVO’s trailing and forward P/E were 19.24 and 17.09, respectively, according to Yahoo Finance. A picture of a […]
Could Ozempic Lower Your Risk of Dementia?
Originally designed to treat type 2 diabetes, GLP-1 medications like Ozempic and Wegovy quickly made it into the hands of every now-formerly hefty person in your life. A new study suggests that these drugs, specifically their active ingredient semaglutide, might be shielding your brain from dementia in addition to melting fat. Researchers at Case Western […]
Novo Nordisk Has Made a Fortune With Ozempic, but It Knows Its Success Won’t Last Forever. So, It Has Already Developed Two Substitutes
The market for weight-loss drugs continues to grow, but the competition for the largest share of this expanding “pie” is intense. The American pharmaceutical giant Eli Lilly and Co. is encroaching on Novo Nordisk’s territory. However, Novo Nordisk, the pioneer behind Ozempic, is now working to regain its lead. It’s doing so with a double […]
Monthly shot cuts body weight by 16% in groundbreaking obesity trial
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful treatment for obesity. With just a once-monthly shot of ‘MariTide,’ participants in the study lost as much as 16% of their body weight over the course of a year. Continue Reading Category: Obesity, Illnesses and […]
The J. M. Smucker Company (SJM) I Told Them Not To Buy Twinkies!, Says Jim Cramer
The J. M. Smucker Company (NYSE:SJM) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks. The J. M. Smucker Company (NYSE:SJM) is a major American food products company. As has been the case with other food companies, such as Pepsi, investors are worried about the firm […]
STAT+: Novo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game
How did Novo Nordisk get to the position it’s in now — with its stock halved over the past year and the company widely seen as trailing Eli Lilly in the weight loss market it once led? “I’m not sure I fully accept the premise of the question,” Martin Lange, Novo’s head of development, responded. […]
Tesla’s Robotaxi Rollout
In this podcast, Motley Fool Chief Investment Officer Andy Cross and contributors Jason Hall and Matt Frankel discuss: Fair Isaac Corp. to include buy now, pay later data. The importance of Tesla‘s robotaxi. Tesla’s advantages and challenges in self-driving. Fiserv launches its own stablecoin. To catch full episodes of all The Motley Fool’s free podcasts, […]
Two ‘Spectacular’ Studies & Other Movement Disorder Updates
Studies on stem cell therapy, GLP-1 drugs, and a new infusion pump are discussed by Professor Diener in this update on movement disorders. Medscape Neurology